Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis

Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study

(2021) Steven Fishbane et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Fr150 GB004 EXHIBITS PROTECTIVE EFFECTS DIRECTLY ON EPITHELIAL CELLS USING EX VIVO ORGANOID AND MONOLAYER CULTURES

(2021) Kristen Taylor Meadows et al.   GASTROENTEROLOGY

Breaking the therapeutic ceiling in drug development in ulcerative colitis

(2021) Dahham Alsoud et al.   Lancet Gastroenterology & Hepatology

Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)

(2021) Jonathan Barratt et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Mucosal inflammation downregulates PHD1 expression promoting a barrier‐protective HIF‐1α response in ulcerative colitis patients

(2020) Eric Brown et al.   FASEB JOURNAL

P066 GB004, A NOVEL GUT-TARGETED PROLYL HYDROXYLASE INHIBITOR FOR INFLAMMATORY BOWEL DISEASE: FIRST-IN-HUMAN, MUTLIPLE-DOSE STUDY IN HEALTHY SUBJECTS WITH GUT BIOPSIES

(2020) Barrett Levesque et al.   GASTROENTEROLOGY

Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial

(2019) Tadao Akizawa et al.   ADVANCES IN THERAPY

Evolving therapeutic goals in ulcerative colitis: towards disease clearance

(2019) Silvio Danese et al.   Nature Reviews Gastroenterology & Hepatology

P051 Phase 1a Safety and Pharmacokinetic Effects of GB004, a Novel Prolyl Hydroxylase Inhibitor and Potential Therapy for Inflammatory Bowel Disease

(2019) Barrett Levesque et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Histological Remission in Ulcerative Colitis

(2019) Thomas Chateau et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Histological Risk Factors to Predict Clinical Relapse in Ulcerative Colitis With Endoscopically Normal Mucosa

(2018) Ryo Ozaki et al.   Journal of Crohns & Colitis

The emerging role of histologic disease activity assessment in ulcerative colitis

(2018) Rish K. Pai et al.   GASTROINTESTINAL ENDOSCOPY

Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response

(2018) Yael Haberman et al.   Nature Communications

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

(2017) Marcus Harbord et al.   Journal of Crohns & Colitis

Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor–Prolyl Hydroxylase Inhibitor for Anemia

(2017) Jennifer L. Ariazi et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Ulcerative colitis

(2017) Ryan Ungaro et al.   LANCET

Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis

(2016) Sunhee Park et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up

(2015) Robert V Bryant et al.   GUT

Oral Delivery of Prolyl Hydroxylase Inhibitor

(2015) Ellen Marks et al.   INFLAMMATORY BOWEL DISEASES

Intestinal IgA production and its role in host-microbe interaction

(2014) Cindy Gutzeit et al.   IMMUNOLOGICAL REVIEWS

Histologic Remission: The Ultimate Therapeutic Goal in Ulcerative Colitis?

(2013) Laurent Peyrin–Biroulet et al.   Clinical Gastroenterology and Hepatology

Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis

(2013) S Keely et al.   Mucosal Immunology

Role of secretory IgA in infection and maintenance of homeostasis

(2012) Blaise Corthésy   AUTOIMMUNITY REVIEWS

A new pharmacological agent (AKB-4924) stabilizes hypoxia inducible factor-1 (HIF-1) and increases skin innate defenses against bacterial infection

(2012) Cheryl Y. M. Okumura et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa

(2012) E. T. Clambey et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adenosine and Hypoxia-Inducible Factor Signaling in Intestinal Injury and Recovery

(2011) Sean P. Colgan et al.   Annual Review of Physiology

Hypoxia and Inflammation

(2011) Holger K. Eltzschig et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss of Prolyl Hydroxylase-1 Protects Against Colitis Through Reduced Epithelial Cell Apoptosis and Increased Barrier Function

(2010) Murtaza M. Tambuwala et al.   GASTROENTEROLOGY

Metabolic Shifts in Immunity and Inflammation

(2010) D. J. Kominsky et al.   JOURNAL OF IMMUNOLOGY

Hypoxia: an alarm signal during intestinal inflammation

(2010) Sean P. Colgan et al.   Nature Reviews Gastroenterology & Hepatology

The Hydroxylase Inhibitor Dimethyloxalylglycine Is Protective in a Murine Model of Colitis

(2007) Eoin P. Cummins et al.   GASTROENTEROLOGY

Mucosal Protection by Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibition

(2007) Andreas Robinson et al.   GASTROENTEROLOGY